Chemotherapy and Radioimmunotherapy Targeting La Autoantigen in Tumors
Author Information
Author(s): Al-Ejeh Fares, Darby Jocelyn M., Brown Michael P.
Primary Institution: Hanson Institute, Adelaide, South Australia, Australia
Hypothesis
Can Yttrium-90 radio-conjugates of a monoclonal antibody effectively target La autoantigen in tumors to enhance cancer treatment?
Conclusion
The study demonstrates that combining chemotherapy with La-targeted radioimmunotherapy significantly prolongs survival in mice with tumors.
Supporting Evidence
- Combining chemotherapy with radioimmunotherapy significantly increased survival rates in tumor-bearing mice.
- Yttrium-90 labeled antibodies showed specific targeting to dead tumor cells.
- Delayed administration of radioimmunotherapy after chemotherapy improved treatment efficacy.
Takeaway
This study shows that a special treatment can help kill cancer cells better when used with chemotherapy, making the treatment more effective.
Methodology
Mice with tumors were treated with Yttrium-90 labeled antibodies either alone or after chemotherapy, and their tumor growth and survival were monitored.
Potential Biases
Potential bias in the selection of tumor models and treatment regimens.
Limitations
The study was conducted in mice, which may not fully represent human responses.
Participant Demographics
Mice bearing established tumors were used in the study.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website